Option Care Health (OPCH) Chief Growth Officer set to exit role May 8, 2026
Rhea-AI Filing Summary
Option Care Health, Inc. announced that Christopher L. Grashoff will depart from his role as Chief Growth Officer, effective May 8, 2026. The company states that Mr. Grashoff will receive separation benefits under its Amended and Restated Executive Severance Plan, subject to a general release of claims in favor of the company and his continued compliance with existing restrictive covenants.
Positive
- None.
Negative
- None.
Insights
Option Care Health discloses its Chief Growth Officer’s upcoming departure with standard severance protections.
Option Care Health, Inc. reports that Chief Growth Officer Christopher L. Grashoff will leave the company effective May 8, 2026. This represents a change in the senior leadership team, but the filing does not provide details on succession or strategic implications.
The disclosure highlights that Mr. Grashoff’s separation benefits follow the company’s Amended and Restated Executive Severance Plan. Payment is conditioned on a general release of claims and adherence to restrictive covenants, which is typical for senior executives and helps manage legal and competitive risk around leadership changes.
8-K Event Classification
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
1 item
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Key Terms
Amended and Restated Executive Severance Plan, general release of claims, restrictive covenants, Emerging growth company
4 terms
Amended and Restated Executive Severance Plan financial
"Mr. Grashoff will be entitled to separation benefits consistent with the Company’s Amended and Restated Executive Severance Plan"
general release of claims regulatory
"which are conditioned upon the effectiveness of a general release of claims in favor of the Company"
restrictive covenants regulatory
"and Mr. Grashoff’s continued compliance with restrictive covenants"
Restrictive covenants are contract terms that limit what a company, its executives, or shareholders can do—like rules that prohibit selling stock, starting a rival business, or taking on certain debts. Think of them as house rules that protect one party’s interests by keeping risky or competitive actions off the table. For investors they matter because these limits affect a company’s flexibility, governance, potential future value and the ease of exiting an investment.
Emerging growth company regulatory
"Emerging growth company Securities registered pursuant to Section 12(b) of the Act"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What executive leadership change did Option Care Health (OPCH) disclose?
Option Care Health disclosed that Chief Growth Officer Christopher L. Grashoff will depart his role effective May 8, 2026. The filing identifies this as a senior leadership change but does not describe any successor or broader organizational restructuring in the provided content.
When is Option Care Health’s Chief Growth Officer Christopher L. Grashoff leaving?
Christopher L. Grashoff is scheduled to depart his role as Chief Growth Officer on May 8, 2026. The company announced the transition on May 5, 2026, providing investors with a clear effective date for this executive leadership change.
What separation benefits will Christopher L. Grashoff receive from Option Care Health (OPCH)?
Christopher L. Grashoff will receive separation benefits consistent with Option Care Health’s Amended and Restated Executive Severance Plan. These benefits are conditioned on an effective general release of claims in favor of the company and his continued compliance with applicable restrictive covenants.
Are there conditions attached to the severance for Option Care Health’s departing Chief Growth Officer?
Yes. Severance for Chief Growth Officer Christopher L. Grashoff is conditioned on a general release of claims in favor of Option Care Health and his ongoing compliance with restrictive covenants, aligning his benefits with legal and competitive protections for the company.
Which SEC form did Option Care Health (OPCH) use to report the Chief Growth Officer’s departure?
Option Care Health reported the Chief Growth Officer’s departure on an Form 8-K under the item covering departure of certain officers and compensatory arrangements. This form is used to disclose material corporate events to shareholders and the broader market.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) | ||||||
(Address of principal executive offices)
(312 ) 940-2443
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
| Title of each Class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On May 5, 2026, Option Care Health, Inc. (the “Company”) announced that Christopher L. Grashoff will depart from his role as Chief Growth Officer of the Company, effective May 8, 2026. Mr. Grashoff will be entitled to separation benefits consistent with the Company’s Amended and Restated Executive Severance Plan, which are conditioned upon the effectiveness of a general release of claims in favor of the Company and Mr. Grashoff’s continued compliance with restrictive covenants.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Option Care Health, Inc. | |||||||||||
| Date: | By: | /s/ Collin Smyser | |||||||||
| Collin Smyser | |||||||||||
| General Counsel and Corporate Secretary | |||||||||||